Pegylated Liposomal Doxorubicin (Caelyx^®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines

REFERENCES

• Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91: 710–717.
   PubMed Web of Science ®Google Scholar
• Hellmann K. Anthracycline cardiac toxicity prevention by dexrazoxane: breakthrough of a barrier-sharpens antitumor profile and therapeutic index (Editorial). J Clin Oncol 1996; 14: 332–333.
   PubMed Web of Science ®Google Scholar
• Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiog-raphy after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7: 141–146.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exu-dates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–992.
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I study. J Clin Oncol 1995; 13: 1777–1785.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxoru-bicin in patients with cancer. Drugs 1997; 54 (suppl 4): 30-35.
   Google Scholar
• O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pe-gylated liposomal doxorubicin 1-ICI (CAELYX174/Doxir) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440–449.
   PubMed Web of Science ®Google Scholar
• Colernan RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomized phase II study of two different schedules of pegylated li-posomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006; 42: 882–887.
   PubMed Web of Science ®Google Scholar
• Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711–716.
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses 500 mg/m2. Ann Oncol 2000; 8: 1029-1033.
   Google Scholar
• Minisini AM, Andreetta C, Fasola G, Puglisi F. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. Expert Rev An-ticancer Ther 2008; 8: 331–342.
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 2003; 4: 318–328.
   PubMedGoogle Scholar
• Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Mar-com PK, et al. Phase I study of Doxil and vinorelbine in metastatic breast can-cer. Ann Oncol 1999; 10: 1113–1116.
   PubMed Web of Science ®Google Scholar
• World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO, Geneva, 1979.
   Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
   Google Scholar
• Slamon DL, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against 1-IER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.
   PubMed Web of Science ®Google Scholar
• Ranson MR, Cheeseman S, White S, Margison J. Caelyx (stealth li-posomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 2001; 37: 115–120.
   PubMed Web of Science ®Google Scholar
• Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin vs vi-norelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893–3901.
   PubMed Web of Science ®Google Scholar
• Potier P. The synthesis of Navelbine prototype of a new series of vin-blastine derivatives. Semin Oncol 1989; 16 (2 Suppl 4): 2-4.
   Google Scholar
• Variol P, Nguyen L, Tranchand B, Puozzo C. A simultaneous oral/in-travenous population pharmacokinetic model. Eur J Clin Pharmacol 2002; 58: 467–476.
   PubMed Web of Science ®Google Scholar
• Bugat R, Variol P, Roche H, Fumoleau P, Robinet G, Senac I. The ef-fect of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol 2002; 50: 285–290.
   PubMed Web of Science ®Google Scholar
• Jassem J, Ramlau R Karnicka-Mlodkowska H, Krawczyk K, Krza-kowski M, Zatloukal P, et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12: 1375–1381.
   Google Scholar
• Puozzo C, Gridelli C. Non-small cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics. Clin Lung Cancer 2004; 5: 237–242.
   PubMedGoogle Scholar
• Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vam-vakas L, et al. Pegylated liposomal doxorubicin in combination with vinorel-bine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol 2006; 58: 742–748.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Carnaghi C, Garassino I. Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer. Breast Cancer Res Trt 2003; 77: 185–188.
   PubMed Web of Science ®Google Scholar
• Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age. Cancer Chemother Pharmacol 2008; 62: 285–292.
   PubMed Web of Science ®Google Scholar
• Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overex-pressing metastatic breast cancer. Clin Breast Cancer 2007; 7: 690–696.
   PubMed Web of Science ®Google Scholar
• Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009; 32: 18–24.
   PubMedGoogle Scholar
• Biganzoli L, Coleman R, Minisini A, Hamilton A, Aapro M, Therasse P, et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (CaelyxTM) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 2007; 61: 84–89.
   PubMed Web of Science ®Google Scholar
• O'Brien MER. Single-agent treatment with pegylated liposomal dox-orubicin for metastatic breast cancer. Anticancer Drugs 2008; 19: 1–7.
   PubMed Web of Science ®Google Scholar